We look to expand our product portfolio and welcome approaches from potential collaborators and strategic partners.
In-Licensing

S.L.A. Pharma is looking to expand its product portfolio with novel ways of treating patients suffering from gastrointestinal disorders. We welcome approaches from potential collaborators with opportunities at various stages of clinical development that fit with our strategic focus.
Out-Licensing

S.L.A. Pharma aims to establish strategic alliances that add value to and enhance the commercial potential of our existing product pipeline, and progress developments as quickly as possible from concept to patients.
 
Our Developments

Development Therapeutic Area
Topical diltiazem Anal Fissure
EPA-FFA Familial Adenomatous Polyposis
Topical metronidazole Crohn's disease
Oral naloxone Opioid induced constipation

For further information please contact:
Business Development: E / info@slapharma.com